Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovative enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from a follower to a leader in innovation [2] Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit attributable to shareholders of 1.702 billion yuan, representing a year-on-year growth of 38.96% [2] - Revenue from innovative drugs exceeded 4.3 billion yuan, with a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [2] Innovation Strategy - The company has approved 4 innovative drugs (covering 5 indications) and 57 generic drugs during the reporting period, with 4 innovative drugs and 22 generic drugs submitted for market approval [3] - Fosun Pharma emphasizes the importance of innovation in drug development efficiency, speed to market, and commercialization [4] Global Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue [5] - The company has established a clinical operations team in the U.S. for the commercialization of innovative products and has set up regional distribution centers in emerging markets [5][6] Business Development - Fosun Pharma's innovative pipeline quality has improved, leading to increased business development activities and global licensing cooperation [6] - The company has achieved significant international recognition for its PD-1 monoclonal antibody, with approvals in over 30 countries and regions [6] Strategic Focus - The company is implementing a new A+H share equity incentive plan, with core performance indicators focusing on net profit and innovative drug revenue [4] - Fosun Pharma aims for a compound annual growth rate of approximately 20% in innovative drug revenue from 2025 to 2027 [4] Long-term Vision - The company is committed to its 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to enhance innovation speed and quality, as well as global reach [8]

Core Viewpoint - Fosun Pharma has transformed from a generic drug company to a high-level innovation-driven enterprise, focusing on innovation and global expansion, reflecting the shift of China's pharmaceutical industry from follower to leader [1] Group 1: Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan and a net profit of 1.702 billion yuan, representing a year-on-year growth of 38.96% [1] - Revenue from innovative drugs exceeded 4.3 billion yuan, marking a year-on-year increase of 14.26%, driven by product structure optimization and sales growth [2] Group 2: Innovation Strategy - The company emphasizes innovation as its core development engine, focusing on unmet clinical needs and core therapeutic areas, while enhancing R&D capabilities and efficiency [1][2] - Fosun Pharma has approved 4 innovative drugs and 57 generic drugs during the reporting period, with nearly 20 innovative drug clinical trials approved by regulatory agencies [2] Group 3: Global Expansion - In the first half of 2025, overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue, with a focus on establishing a commercial presence in the U.S. market [3] - The company has built a mature commercialization system, with over 1,000 personnel in its overseas commercialization team, and aims to deepen international cooperation [4] Group 4: Strategic Initiatives - Fosun Pharma plans to launch a new A+H share equity incentive plan, with core performance indicators focusing on net profit and innovative drug revenue [2] - The company adheres to the 4IN strategy: Innovation, Internationalization, Intelligentization, and Integration, aiming to accelerate progress in these areas [6]

Core Viewpoint - Fosun Pharma has demonstrated strong financial performance in the first half of the year, with a net profit of 1.702 billion yuan, representing a year-on-year increase of 38.96% [2][3] Financial Performance - In the first half of the year, Fosun Pharma achieved operating revenue of 19.514 billion yuan, with innovative drug revenue exceeding 4.3 billion yuan, a year-on-year growth of 14.26% [2][3] Innovation Strategy - Innovation remains the core engine for Fosun Pharma's growth, with a focus on diverse R&D models including self-development, collaboration, licensing, and investment [3][4] - The company has made significant progress in its pipeline, with 4 innovative drugs and 57 generic drugs approved during the reporting period, and nearly 20 innovative drug clinical trials approved [4] Strategic Direction - The company continues to adhere to its "4IN" strategy, focusing on Innovation, Internationalization, Intelligentization, and Integration [4][5] - The emphasis on innovation is expected to accelerate in terms of speed and quality, as well as global outreach and AI integration [4] International Expansion - Fosun Pharma aims to become a global Big Pharma, with overseas revenue reaching 5.478 billion yuan, accounting for 28.07% of total revenue [5][6] - The company is expanding its international market presence through partnerships and local registrations, particularly in emerging markets like the Middle East and Southeast Asia [6][7] Business Development Strategy - The company maintains a balanced approach between license-in and license-out strategies to enhance its product pipeline and support its global expansion [7] - Business development is seen as a crucial pathway for Fosun Pharma to enhance its global footprint and capabilities [7]